Kornimate/medical-research-clean huggingface dataset:
bone marrow derived adult stem cells for acute anterior myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: study hypothesis : the purpose of this study is to determine whether intracoronary infusion of autologous bone marrow derived progenitor cells to patients undergoing primary angioplasty for acute anterior myocardial infarction will lead to an improvement in cardiac function greater than that seen by placebo alone. aims * to demonstrate that it is safe and feasible to deliver autologous bone marrow derived stem cells within hours of the primary angioplasty procedure * to demonstrate the effects of autologous bone marrow derived stem cells on cardiac function using cardiac mri (or cardiac ct), echocardiography and left ventriculography. * to demonstrate the effect of autologous bone marrow derived stem cells in addition to standard care leads to improvement in cardiac function compared to patients saline(placebo) and standard care.


Eligibility criteria:
inclusion criteria: * patients presenting to the heart attack centre with acute anterior myocardial infarction (st elevation in at least 2 contiguous anterior leads ≥ 0.2 mv) and treated with acute pci with stent implantation within 24 hours after symptom onset * acute pci / stent implantation has been successful (residual stenosis visually \< 30% and timi flow ≥ 2). * at the time of inclusion patient no longer requires i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump) * significant regional wall motion abnormality in lv angiogram at the time of acute pci in the lad territory * age 18 - 80 years (primary angioplasty confers an adverse prognosis in those over the age of 80 years) * written informed consent in the recruiting centres native language exclusion criteria: * regional wall motion abnormality outside the area involved in the index acute myocardial infarction * need to revascularise additional vessels, outside the infarct artery as a planned procedure (these vessels can be treated at baseline) * arteriovenous malformations or aneurysms * active infection, or fever or diarrhoea within last 4 weeks * chronic inflammatory disease * known hiv infection or active hepatitis * neoplastic disease without documented remission within the past 5 years * cerebrovascular insult within 3 months * impaired renal function (creatinine \> 200mmol) at the time of cell therapy * significant liver disease (got \> 2x upper limit) or spontaneous inr \> 1,5) * anemia (hemoglobin \< 8.5 mg/dl) * platelet count \< 100.000/µl * hypersplenism * known allergy or intolerance to clopidogrel, heparin or abciximab * history of bleeding disorder * gastrointestinal bleeding within 3 months * major surgical procedure or trauma within 2 months * uncontrolled hypertension * pregnancy * mental retardation leading to inability to obtain informed consent * previously performed stem / progenitor cell therapy * participation in another clinical trial within the last 30 days

Keywords: heart attack anterior myocardial infarction (mi) adult stem cells bone marrow progenitor cells bone marrow stem cells autologous left ventricular function intracoronary injection
effect of piezoelectric surgery on pain, comfort, and patient satisfaction in third molar surgery

Conditions: Oral Complication

Summary: the purpose of this study is to compare the effects of piezoelectric surgery on postoperative pain, comfort and patient satisfaction with conventional bur method applied in surgical extraction of impacted mandibular third molars. the main question it aims to answer is: is piezoelectric surgery effective on reducing pain and increasing comfort and patient satisfaction in impacted third molar surgery? pain levels were assessed using the visual analog scale (vas), and patient satisfaction was measured with functional evaluations conducted on the 1st, 3rd, and 7th postoperative days.


Eligibility criteria:
inclusion criteria: * patients with mesioangular, distoangular, vertical or horizontal, fully impacted and fully bone retained impacted lower wisdom teeth * patients without any systemic disease * patients who have been informed about the duration, purpose and requirements of the study and who have signed the informed consent form voluntarily. exclusion criteria: * patients with any systemic contraindication, infection in the area of the tooth to be extracted, anamnesis of sensitivity to paracetamol derivatives or aspirin, pregnant or breastfeeding patients, and patients using antibiotics or anti-inflammatory drugs in the last 3 weeks * in addition, smokers or alcohol addicts were not included in the study.
effectiveness of a home-based cognitive rehabilitation program in patients with mci

Conditions: Cognitive Impairment; Mild Cognitive Impairment

Summary: in this study, a more specific and systematic home-based cognitive rehabilitation program driven by a tablet application is developed and the purpose of the program is to check whether cognitive function is improved when the program is applied to patients with mci.

the subjects of recruitment were the elderly with mild cognitive impairment living in the local community. assessments were conducted 7 days before and after the intervention. subjects received korean-montreal cognitive assessment(moca), semantic verbal emory test (svlt), number memorization test; digit span test (dst), category word fluency test (cwft), phonemic word fluency test (pwft), korean-mini mental state test (k-mmse), and geriatric depression scale (gds) before and 8 weeks after the intervention.

Eligibility criteria:
inclusion criteria: 1. men and women over the age of 55 2. those who have visual and auditory abilities without difficulties in conducting this research 3. those with k-mmse (korean-mini mental state examination) score of 24 or higher and 16≤k-moca score\<23 4. in the case of patients taking dementia treatment, those who have the same treatment regimen and dose for 3 months or more from the screening date 5. a person who can understand and respond to the questionnaire questions. 6. a person who voluntarily decided to participate in this study and gave written consent to the informed consent form exclusion criteria: 1. those with a history of alcohol or drug abuse, 2. those with a past history of uniaxial psychiatric disorders, including intellectual disability, schizophrenia, alcoholism, and bipolar disorder 3. a person who is unable to communicate 4. those who show all neurological symptoms that cause cognitive decline, such as parkinson's disease, cerebral hemorrhage, brain tumor, and hydrocephalus 5. those with a record of being unconscious for more than 1 hour due to head trauma or mild repetitive head trauma 6. those with symptoms of depression that may affect cognitive function
robotic rehabilitation vs occupational therapy chronic stroke upper limb rehabilitation

Conditions: Chronic Stroke

Summary: the functional recovery of the upper limb represents a critical element in post-stroke rehabilitation; hemiplegic/hemiparetic patients who achieve optimal recovery are a minority, and incomplete recovery has relevant consequences both on functioning and on quality of life of those who survive a stroke. the project aims to assess the effects on the functional recovery, with manual dexterity as the primary outcome, of a treatment protocol using an innovative tool (gloreha sinfonia) that enables assisted execution of three-dimensional tasks combined with serious games for cognitive stimulation, targeting the functional recovery of the upper limb in patients with stroke outcomes at least 6 months after the acute event (chronic phase). patients with residual dysfunction of the upper limb, at least 6 months after the stroke, will be randomly assigned to the robotic rehabilitation group (robot), the occupational therapy group (ot), focused on the use of the upper limb in functional tasks (task-oriented training), or the control group (ct - prescription of a home exercise program). patients in the robot and ot groups will undergo a total treatment period of 5 weeks, with 3 sessions per week lasting 1 hour, for a total of 15 sessions/hours of treatment. patients assigned to the ct group will undergo an initial functional assessment required for defining the exercise program. all patients will be evaluated at baseline (t0), at a 5-week interval (t1), and 6 months after the end of treatment (t2). outcome indicators include measures of manual dexterity/upper limb performance, anxiety/depression, cognitive abilities, and patient-perceived outcomes. the analysis of surface plasmon resonance imaging (spri) of serum exosome content, detected at t0, t1, and t2, will be correlated with variations in functional measures to verify the hypothesis that induction of neuroplasticity underlies any observed changes. short- and medium-term effects on functional, psychological outcomes, as well as indicators of neuroinflammation and neural regeneration from serum analysis using innovative spri, will be compared among the 3 groups.


Eligibility criteria:
inclusion criteria: 1. first ischemic or hemorrhagic stroke occurring at least 6 months prior. 2. persistent motor deficit in the affected upper limb (motricity index between 18 and 77). 3. willingness to participate in the study, with the provision of informed consent. exclusion criteria: 1. severe spastic hypertonia at the wrist and fingers (modified ashworth scale equal to or greater than 3). 2. orthopedic, rheumatological, and/or peripheral nervous system disorders affecting the paretic upper limb. 3. neurodegenerative and neuromuscular disorders. 4. acute pathologies affecting other body systems. 5. severe cognitive, language, and behavioral disorders that significantly limit understanding and participation in the planned activities.

Keywords: robotic rehabilitation occupational therapy chronic stroke upper limb impairment biomarkers manual dexterity
effect of different concentrations of sparc1102 on allergic conjunctivitis

Conditions: Allergic Conjunctivitis

Summary: the present study will test if administration of different concentrations of 1334h eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.


Eligibility criteria:
inclusion criteria: * signed informed consent form and hipaa document * willing and able to comply with all study procedures * be at least 10 years of age at the time of enrollment * logmar 0.7 or better, in each eye * history of ocular allergies, and a positive skin and ocular allergic reaction to allergens * a negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period exclusion criteria: * have known contraindications or sensitivities to the use of any of the study medications(s) or their components; * have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium or a diagnosis of dry eye); * have a current diagnosis or history of open angle glaucoma or ocular hypertension; * have had ocular surgical intervention within three (3) months prior to visit 1 or during the study and/or a history of refractive surgery within the past 6 months; * have a known history of retinal detachment, diabetic retinopathy, or progressive retinal disease; * have the presence of an active ocular infection (bacterial, viral or fungal), positive history of an ocular herpetic infection, or preauricular lymphadenopathy at any visit; * manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at screening or during study * have used an investigational drug or device within 30 days of the study or be concurrently enrolled in another investigational drug or device study within 30 days of the study
safety and efficacy of once daily topical treatment with leo 90100 aerosol foam in adolescent subjects with plaque psoriasis

Conditions: Psoriasis Vulgaris

Summary: an international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.


Eligibility criteria:
inclusion criteria (all subjects) * psoriasis vulgaris on trunk and/or limbs affecting at least 2% bsa. * psoriasis vulgaris on the scalp affecting at least 10% of total scalp area. * a total psoriatic involvement on trunk, limbs and scalp not exceeding 30% bsa. * pga score of at least mild on trunk and/or limbs at sv1, sv2 and v1. * pga score of at least mild on scalp at sv1, sv2 and v1. * a serum albumin-corrected calcium below the upper reference limit at sv2. inclusion criteria (for subjects performing hpa axis assessment) * psoriasis vulgaris on trunk and/or limbs affecting at least 10% bsa. * psoriasis vulgaris on the scalp affecting at least 20% of total scalp area. * pga score of at least moderate on trunk and limbs at sv1, sv2 and v1. * pga score of at least moderate on scalp at sv1, sv2 and v1. * normal hpa axis function at sv2 (serum cortisol concentration above 5 mcg/dl before acth challenge and serum cortisol concentration above 18 mcg/dl 30 minutes after acth challenge). exclusion criteria (all subjects): * a history of hypersensitivity to any component of leo 90100. * systemic treatment with biological therapies (marketed or not marketed), with a possible effect on scalp and/or body psoriasis within the following time period prior to v1 and during the trial: 1. etanercept - within 4 weeks prior to v1 2. adalimumab, infliximab - within 2 months prior to v1 3. ustekinumab - within 4 months prior to v1 4. experimental products - within 4 weeks/5 half-lives (whichever is longer) prior to v1 * systemic treatment with therapies other than biologicals, with a possible effect on scalp and/or body psoriasis (e.g. methotrexate, retinoids, immunosuppressants) within 4 weeks prior to v1 or during the trial. * puva therapy within 4 weeks prior to v1. * uvb therapy within 2 weeks prior to v1 or during the trial. exclusion criteria (for subjects performing hpa axis assessment): * a history of serious allergy, allergic asthma or serious allergic skin rash. * known or suspected hypersensitivity to any component of cortrosyn® (including acth/cosyntropin/tetracosactide) * systemic treatment with corticosteroids (including inhaled and nasal steroids) within 12 weeks prior to sv2 or during the trial. * oestrogen therapy (including contraceptives) or any other medication known to affect cortisol levels or hpa axis integrity within 4 weeks prior to sv2 or during the trial.
kirschner wires fixation versus cannulated screws internal fixation for displaced lateral condyle humeral fracture in children

Conditions: Lateral Condyle Humerus Fracture in Children

Summary: lateral condyle fracture of the distal humerus is the second most common injury around the elbow and accounts for 20% of all the elbow fractures in children.the average age for the fracture involving the lateral condyle is around six years. there are different treatment options of the lateral condyle fractures include * non-operative management with plaster cast immobilization for undisplaced or minimally displaced fractures. * whereas the fractures displaced \>2 mm need operative management. the objective of treatment in the displaced fracture is to obtain and maintain the articular congruity. in the operative management, the reduction technique includes open or closed methods.


Eligibility criteria:
inclusion criteria: * children up to 14 years. * closed lateral condylar fracture. * displacement more than 2mm . * fracture less than two weeks of injury. exclusion criteria: * patients with open fractures. * otherassociated injury in the same elbow . * elbow with preexisting anatomical deformity .
clinical, meibographic and interferometric evaluation of phlyctenular keratitis in children - meibo-rosacee

Conditions: Ocular Rosacea; Keratoconjunctivitis; Meibomian Gland Dysfunction

Summary: the aim of this study is to describe the clinical, meibographic and interferometric manifestations of phlyctenular keratitis in children.

the investigators are conducting a monocentric, transversal, epidemiologic study. 100 patients should be included: 50 children suffering from ocular rosacea, and 50 children with no palpebral or meibomian disease. witnesses will be matched on the age of the cases. patient and controls will undergo a classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. then, the child will go through a meibographic and interferometric evaluation of his two inferior eyelids. this evaluation is made by an optometrist with the lipiview device, and lasts a few minutes.

Eligibility criteria:
inclusion criteria: * recruited from a specialized ophthalmologic consultation rothschild ophthalmologic foundation, paris, france. * cases : suffering from ocular or oculo-cutaneous rosacea * witnesses : without any present or past palpebral or meibomian disease exclusion criteria: * unable to achieve the meibographic and interferometric examination (lipiview)

Keywords: ocular rosacea keratoconjunctivitis meibomian gland interferometry child
a prospective study of clinical outcomes for the pathwork tissue of origin test

Conditions: Neoplasm Metastasis

Summary: the study prospectively assesses the change in cancer-specific clinical decisions and outcomes before and after physicians received results from the pathwork® tissue of origin (too) test for patients whose primary site of cancer origin is uncertain.


Eligibility criteria:
inclusion criteria: * their physician ordered or intends to order a pathwork® too test between may 2012 and december 2013 * the patient is ≥ 18 years of age * the patient has given informed consent (online or verbal) * the patient is able to understand english.

Keywords: neoplasms neoplasm metastasis neoplastic processes pathologic processes
long-chain fatty acid oxidation disorders in-clinic disease monitoring program

Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Summary: the primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with lc-faod who are enrolled in the dmp.

the lc-faod disease monitoring program (dmp) is an international, long-term, retrospective and prospective outcomes study aiming to collect safety and effectiveness data for triheptanoin and the natural history of lc-faod for a study duration of up to 10 years from adult and pediatric patients with lc-faod, with any previous disease management, regardless of prior treatment with triheptanoin, those who have previously participated in triheptanoin clinical trials, and those who received triheptanoin through an expanded access program (eap). patients enrolling in the lc-faod dmp will be managed at the discretion of their physicians and may or may not be treated with triheptanoin during the course of the study. patients will have access to triheptanoin only through authorized commercial use (if approved in their country) or available eap but not from the lc-faod dmp itself.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of any lc-faod subtype. diagnosis must be confirmed by results of acylcarnitine profiles and/or genetic testing results obtained from medical records or equivalent documentation. * willing and able to comply with all study procedures. * willing and able to provide consent or, if a minor, provide assent and informed consent by their legally authorized representative. * females of childbearing potential who become pregnant during the study will be invited to remain in the study. pregnant females with lc-faod will be informed of the study and invited to enroll. exclusion criteria: * presence of a concurrent disease or condition that would interfere with study participation or affect patient's safety in the opinion of the investigator. * presence or history of any condition that, in the view of the investigator, places the patient at high risk of not completing the study or would affect the interpretation of study results.

Keywords: cact deficiency carnitine acylcarnitine translocase deficiency cpt1 cpt2 carnitine palmitoyltransferase deficiencies vlcad very long chain acyl coa dehydrogenase deficiency lchad deficiency long-chain 3-hydroxyacyl-coa dehydrogenase deficiency tfp deficiency trifunctional protein deficiency
optimizing maintenance therapy in copd patients

Conditions: COPD

Summary: background: effectiveness of maintenance therapy for copd with dry powder inhalers (dpis) requires an optimal peak inspiratory flow rate (pifr), a proper inhalation technique and adequate medication adherence from patients. recent studies have suggested that patients with reduced peak inspiratory flow may have worse copd-related symptom burden and increased risk of copd-related hospitalizations. however, in primary care, little is known about how many copd patients have suboptimal pifr. furthermore, there is a paucity of knowledge concerning the associations of pifr, inhalation technique and medication adherence with the effectiveness of maintenance therapy. objective: to examine associations of pifr, inhalation technique, and medication adherence with health status and disease, exacerbations, and healthcare resource utilization in patients with copd receiving maintenance treatment with dry powder inhalers. study design: cross-sectional observational study in five european countries\*. study population: copd patients aged 40 years or older who have received copd maintenance therapy through dpis in the past 3 months or longer. main study parameters: health status as measured with the clinical copd questionnaire (ccq), copd assessment test (cat), number of exacerbations, an assessment of pifr, inhalation technique errors, medication adherence, healthcare resource utilization (hcru), medication use and demographic and clinical covariates. nature and extent of the burden and risks associated with participation, benefit and group relatedness: no significant burden from participating is expected. risk of participating is deemed negligible. in addition, patients may benefit from participating. specifically, patients who manifest inhalation errors, will receive a tailored inhalation instruction to remediate their inhalation errors. the impact of this instruction will not be evaluated in any way, therefore it should not be seen as an intervention. \* if the preplanned number of patients cannot be included also because of national outbreaks of sars-cov-2 resulting in travel restrictions, participation will be sought from researchers from three other european countries


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of copd; * age ≥ 40; * use of maintenance therapy through a dpi in the last 3 months or longer * sufficient investigator-assessed decision-making capacity to provide informed consent (patients will not be invited if they have acute psychotic disorders, severe pervasive developmental disorders / severe intellectual disability or advanced neurodegenerative disease) exclusion criteria: * an exacerbation in the past 6 weeks (as this requires a patient to recover) * life threatening disease and life expectancy \< 6 months (as inclusion of these patients is unethical) * participation in a randomized clinical trial on copd medication

Keywords: copd exacerbations primary care inhalation medication epidemiology treatment